Literature DB >> 7583441

The 90K tumor-associated antigen and clinical progression in human immunodeficiency virus infection.

S Iacobelli1, A Ullrich, N Tinari, L Ortona, E Tamburrini, M D'Egidio, F Ghinelli, L Sighinolfi, M Piazza, A Chirianni.   

Abstract

We investigated the possibility that a secreted glycoprotein of approximately 90,000 daltons, termed 90K and identified as a member of the protein superfamily characterized by the scavenger receptor cysteine-rich (SRCR) domain, might have value as a predictor of progression to acquired immunodeficiency syndrome (AIDS) in subjects infected with the human immunodeficiency virus (HIV). Among 488 HIV-seropositive intravenous drug users with a median follow-up of 32.5 months, high levels of serum 90K at baseline proved to be a significant predictor of faster progression to AIDS, either as a continuous variable (log 90K; p < 0.0001) or as a dichotomous variable with an optimized cutoff point of 30 U/ml (p < 0.00001). Analysis of 90K in relation to known prognostic factors found an association with CD4 count, beta 2-microglobulin, and p24 antigen but none with neopterin. In multivariate analysis, the baseline 90K level was an independent predictor of AIDS. As compared with subjects with low levels of 90K, the relative risk of developing AIDS was 3.5 (95% CI 1.9-6.5) among those with high levels of 90K. The predictive value of 90K was maintained after stratification by baseline CD4 count: among subjects with > or = 500 x 10(6)/L CD4 cells, the proportion in whom AIDS developed was 10.5% for those with 90K levels < or = 30 U/ml as compared with 20% for those with 90K above the cutoff point (p = 0.006). Serum 90K is an independent predictor of the risk for progression to AIDS in HIV-infected subjects, including those whose CD4 counts have not fallen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7583441     DOI: 10.1097/00042560-199512000-00008

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  6 in total

1.  Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy.

Authors:  E C Darcissac; V Vidal; X De La Tribonniere; Y Mouton; G M Bahr
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family.

Authors:  B Silvestri; F Calderazzo; V Coppola; A Rosato; S Iacobelli; C Natoli; A Ullrich; I Sures; M Azam; C Brakebush; L Chieco-Bianchi; A Amadori
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

3.  During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.

Authors:  Lenche Kostadinova; Carey L Shive; Chelsey Judge; Elizabeth Zebrowski; Anita Compan; Kelsey Rife; Amy Hirsch; Yngve Falck-Ytter; Daniela M Schlatzer; Xiaolin Li; Mark R Chance; Benigno Rodriguez; Daniel L Popkin; Donald D Anthony
Journal:  J Infect Dis       Date:  2016-08-17       Impact factor: 5.226

Review 4.  A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus.

Authors:  Christoffer T Nielsen; Ole Østergaard; Niclas S Rasmussen; Søren Jacobsen; Niels H H Heegaard
Journal:  Clin Proteomics       Date:  2017-04-08       Impact factor: 3.988

5.  Increased Gal-3BP plasma levels in hospitalized patients infected with SARS-CoV-2.

Authors:  Valentina Gallo; Roberta Gentile; Giovanni Antonini; Stefano Iacobelli
Journal:  Clin Exp Med       Date:  2022-01-25       Impact factor: 3.984

6.  Cyclophilin C-associated protein (CyCAP) knock-out mice spontaneously develop colonic mucosal hyperplasia and exaggerated tumorigenesis after treatment with carcinogen azoxymethane.

Authors:  Emina Emilia Torlakovic; Vicki Keeler; Chang Wang; Hyun J Lim; Leslie Ann Lining; Suzanne Laferté
Journal:  BMC Cancer       Date:  2009-07-24       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.